Vaccination, squalene and anti-squalene antibodies: Facts or fiction?

European Journal of Internal Medicine

Volumn 21, Issue 2, 2010, Pages 70-73

  Lippi, Giuseppe ^a   Targher, Giovanni ^b   Franchini, Massimo ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Antibodies; Autoantibodies; Influenza; Squalene; Vaccination

Indexed keywords

ANTHRAX VACCINE; ANTIBODY; INFLUENZA VACCINE; SQUALENE; SQUALENE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY TITER; DISEASE ASSOCIATION; EVIDENCE BASED PRACTICE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INJECTION SITE PAIN; NONHUMAN; PERSIAN GULF SYNDROME; SHORT SURVEY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTHRAX VACCINES; ANTIBODIES; AUTOANTIBODIES; HUMANS; PERSIAN GULF SYNDROME; SQUALENE; VACCINES;

EID: 77549088441     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2009.12.001     Document Type: Short Survey

References (23)

1. Bloch K.E. Sterol structure and membrane function. CRC Crit Rev Biochem 14 (1983) 47-92
2. Huang Z.R., Lin Y.K., and Fang J.Y. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules 14 (2009) 540-554
3. Tagliabue A., and Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 4 (2008) 347-349
4. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., and Hennig R. Safety of MF59 adjuvant. Vaccine 26 (2008) 3209-3222
5. Banzhoff A., Pellegrini M., Del Giudice G., Fragapane E., Groth N., and Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi Viruses 2 (2008) 243-249
6. Dormitzer PR, Rappuoli R, Casini F, et al. Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Currents: influenza 2009. Available at http://knol.google.com/k/adjuvant-is-necessary-for-a-robust-immune-response-to-a-single-dose-of-h1n1. Last accessed : 28 November 2009.
7. Clark TW, Pareek M, Hoschler K, et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine - preliminary report. N Engl J Med 2009 Sep 10, Electronic publication.
8. Vesikari T., Pellegrini M., Karvonen A., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 28 (2009) 563-571
9. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med. 2009 Oct 5 (Electronic publication).
10. Gronseth G.S. Gulf war syndrome: a toxic exposure? A systematic review. Neurol Clin 23 (2005) 523-540
11. Asa P.B., Cao Y., and Garry R.F. Antibodies to squalene in Gulf War syndrome. Exp Mol Pathol 68 (2000) 55-64
12. Alving C.R., and Grabenstein J.D. Re: antibodies to squalene in Gulf War Syndrome. Exp Mol Pathol 68 (2000) 196-198
13. Asa P.B., Wilson R.B., and Garry R.F. Antibodies to squalene in recipients of anthrax vaccine. Exp Mol Pathol 73 (2002) 19-27
14. Matyas G.R., Wassef N.M., Rao M., and Alving C.R. Induction and detection of antibodies to squalene. J Immunol Methods 245 (2000) 1-14
15. Matyas G.R., Rao M., and Alving C.R. Induction and detection of antibodies to squalene. II. Optimization of the assay for murine antibodies. J Immunol Methods 267 (2002) 119-129
16. Matyas G.R., Rao M., Pittman P.R., et al. Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice. J Immunol Methods 286 (2004) 47-67
17. Del Giudice G., Fragapane E., Bugarini R., et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 13 (2006) 1010-1013
18. Phillips C.J., Matyas G.R., Hansen C.J., Alving C.R., Smith T.C., and Ryan M.A. Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. Vaccine 27 (2009) 3921-3926
19. In: Fulco C.A., Liverman C.T., and Sox H.C. (Eds). Gulf War and Health. Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, Vaccines (2000), Institute of Medicine, National Academy Press, Washington, DC
20. Everson M.P., Shi K., Aldridge P., Bartolucci A.A., and Blackburn W.D. Immunological responses are not abnormal in symptomatic Gulf War veterans. Ann NY Acad Sci 966 (2002) 327-342
21. Kuroda Y., Nacionales D.C., Akaogi J., Reeves W.H., and Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 58 (2004) 325-337
22. O'Hagan D.T., Wack A., and Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?. Clin Pharmacol Ther 82 (2007) 740-744
23. Podda A., and Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2 (2003) 197-203